Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 09, 7:10 AMBarclays downgrades Fresenius Medical Care to underweight and cuts price target to €35 on expected reimbursement, volume and inflation pressures on earnings
Index
-
Market Cap
11.48B
Enterprise Value
23.69B
Income
955.84M
Sales
22.63B
Book/sh
28.00
Cash/sh
2.41
Employees
111024
IPO
Sep 17, 1996
P/E
12.73
Forward P/E
10.06
PEG
13.60
P/S
0.51
P/B
0.79
P/C
9.20
P/FCF
5.53
EV/EBITDA
5.62
EV/Sales
1.05
Quick Ratio
0.69
Current Ratio
0.99
Debt/Eq
0.85
LT Debt/Eq
0.62
Option/Short
Yes / Yes
EPS (ttm)
1.74
EPS next Y
2.20
EPS next Q
0.56
EPS this Y
-9.26%
EPS next Y
-3.83%
EPS next 5Y
0.74%
EPS past 3/5Y
16.25% -3.43%
Sales past 3/5Y
2.83% 1.71%
EPS Y/Y TTM
26.14%
Sales Y/Y TTM
4.27%
EPS Q/Q
-36.42%
Sales Q/Q
-0.50%
Insider Own
0.00%
Insider Trans
-
Inst Own
8.68%
Inst Trans
0.53%
ROA
2.65%
ROE
6.43%
ROIC
4.06%
Gross Margin
26.46%
Oper. Margin
11.23%
Profit Margin
4.22%
SMA20
-1.69%
SMA50
-0.90%
SMA200
-3.44%
Trades
Shs Outstand
519.02M
Shs Float
519.01M
52W High
26.42 -16.28%
52W Low
20.02 10.49%
Volatility
1.87% 1.95%
ATR (14)
0.60
RSI (14)
46.57
Beta
0.74
Rel Volume
3.70
Avg Volume
972.45K
Volume
1,985,006
Perf Week
-4.61%
Perf Month
4.93%
Perf Quarter
-6.39%
Perf Half Y
3.41%
Perf YTD
-7.14%
Perf Year
-7.79%
Perf 3Y
28.68%
Perf 5Y
-33.45%
Perf 10Y
-44.49%
Prev Close
22.74
Price
22.12
Change %
-2.73%
Consensus
Sell
Avg. Price Target
$20.38
Implied Upside
-7.9%
Analysts13incl. previous ratings
Rating Distribution1 Buy · 5 Hold · 7 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 09, 2026Downgrade
BCS logoBBarclays
Equal Weight → Underweight
Sep 29, 2026Downgrade
BBerenberg
Buy → Hold
Jul 28, 2026Downgrade
BBNP Paribas Exane
Neutral → Underperform$19.90-10.0%
Jul 16, 2026Initiated
BBernstein
Mkt Perform
Jan 20, 2026Downgrade
GS logoGGoldman
Buy → Neutral
Oct 15, 2025Downgrade
BAC logoBBofA Securities
Neutral → Underperform
Sep 02, 2025Downgrade
UBS logoUUBS
Neutral → Sell
Dec 02, 2024Upgrade
BAC logoBBofA Securities
Underperform → Neutral
Nov 06, 2024Initiated
BBerenberg
Buy$25.60+15.7%
Jan 08, 2024Downgrade
MS logoMMorgan Stanley
Equal-Weight → Underweight
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
CEO & Chairman of the Management BoardMr. Shervin J. Korangy
CFO & Member of the Management BoardMr. Martin Fischer
Member of the Management BoardDr. Jorg Haring
CEO of Care Enablement & Member of Management BoardMr. Joseph E. Turk Jr.
Global Chief Medical Officer & Member of Management BoardDr. Charles Hugh-Jones M.D.